Sawyers Charles L
Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Cell. 2009 May 29;137(5):796-8. doi: 10.1016/j.cell.2009.05.011.
Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue (Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations.
激酶抑制剂开创了靶向治疗的时代，但迄今为止它们的效用主要局限于携带致癌激酶突变的癌症。本期的两篇论文（Luo等人，2009年；Scholl等人，2009年）通过揭示RAS突变肿瘤中激酶特异性的脆弱性，可能会改变这一局面。
